Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
about
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Cabozantinib is well tolerated ...... e kinase domain/F691 mutation.
@en
Cabozantinib is well tolerated ...... e kinase domain/F691 mutation.
@nl
type
label
Cabozantinib is well tolerated ...... e kinase domain/F691 mutation.
@en
Cabozantinib is well tolerated ...... e kinase domain/F691 mutation.
@nl
prefLabel
Cabozantinib is well tolerated ...... e kinase domain/F691 mutation.
@en
Cabozantinib is well tolerated ...... e kinase domain/F691 mutation.
@nl
P2093
P2860
P356
P1433
P1476
Cabozantinib is well tolerated ...... e kinase domain/F691 mutation.
@en
P2093
Andrew M Brunner
Ashley M Perry
Aura Y Ramos
Christelle Joseph
Christine Connolly
Daniela Hernandez
David E Avigan
Donna S Neuberg
Emma K Logan
Gabriela Hobbs
P2860
P304
P356
10.1002/CNCR.31038
P407
P50
P577
2017-09-28T00:00:00Z